Clopidogrel causes the lowest risk of bleeding, followed by ticagrelor, and so, clopidogrel should be an agent of choice from the group of P2Y12 inhibitors [20]. DOACs (apixaban, rivaroxaban, and edoxaban) have a favorable risk-benefit profile with a considerable reduction in stroke, intracranial bleeding, and mortality and comparable major bleeding as VKA, but increased gastrointestinal bleeding [21]. Here, P2RY12 is linked to Stroke.